New and Investigational Agents for Irritable Bowel Syndrome (Q38601834)

4 September 2017

title

New and Investigational Agents for Irritable Bowel Syndrome (English)

1 reference

4 September 2017

2

Michael Camilleri

1 reference

4 September 2017

Akhilesh Wadhwa

1

1 reference

4 September 2017

Madhusudan Grover

series ordinal

3

1 reference

4 September 2017

publication date

1 December 2015

1 reference

Current gastroenterology reports

4 September 2017

published in

1 reference

4 September 2017

volume

17

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

46

1 reference

The economic consequences of irritable bowel syndrome: a US employer perspective

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

The association between prucalopride efficacy and constipation type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Bile acids and colonic motility in the rabbit and the human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Medication management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Pharmacological properties of tiropramide, an antispasmodic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effect of otilonium bromide on contractile patterns in the human sigmoid colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Antibiotic treatment of constipation-predominant irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-015-0473-X

Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome

21 January 2018

1 reference

12 December 2020

Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study

1 reference

12 December 2020

Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

1 reference

12 December 2020

Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride

1 reference

12 December 2020

Randomised controlled trial of mesalazine in IBS.

1 reference

12 December 2020

Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders

1 reference

12 December 2020

Possible mechanisms of action of the antispasmodic agent tiropramide in the isolated detrusor from rats

1 reference

12 December 2020

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

1 reference

12 December 2020

Efficacy and Safety of PPC-5650 on Experimental Rectal Pain in Patients with Irritable Bowel Syndrome

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

10.1007/S11894-015-0473-X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1023051690

0 references

Fatcat ID

release_qrzqf3dlo5grflfrky4fwtl3ci

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qrzqf3dlo5grflfrky4fwtl3ci

24 November 2022

mapped directly with Wikidata item

1 reference